Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17683439 | 0.93 | SIRT2 (0.45) | SIRT2SIRT1SIRT3SIRT5ITGB3 | |
| SCHEMBL23347054 | 0.93 | SIRT2 (0.45) | SIRT2SIRT1SIRT3SIRT5ITGB3 | |
| SCHEMBL21205432 | 0.91 | SIRT2 (0.48) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26170667 | 0.90 | CPB1 (0.47) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL24809330 | 0.89 | SIRT2 (0.46) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL24329149 | 0.88 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5ITGB3 | |
| SCHEMBL24728294 | 0.88 | SIRT2 (0.46) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL19681568 | 0.88 | ITGB3 (0.42) | SIRT2SIRT1ITGB3ITGA2B | |
| SCHEMBL23189264 | 0.88 | ITGB3 (0.42) | SIRT2SIRT1ITGB3ITGA2B | |
| SCHEMBL25564468 | 0.87 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836813-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | GENZYME CORPORATION (US) | 2020-11-17 | — | — | US | disclosed |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | GENZYME CORPORATION | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836813-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | FCGR3B, FCGRT, FCGR2A | SIRT2 4648/4885SIRT1 4584/4885SIRT3 4649/4885 |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | FCGR3B, FCGRT, FCGR2A | SIRT2 4648/4885SIRT1 4584/4885SIRT3 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.